BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
CV Sciences, Inc. CVSI
15 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 13.8M
Revenue, FY2025 · full 15-year series below
Revenue $M
Net income $M
FY2025 · Revenue 13.8 · Net income -1.0
Compound annual growth
Revenue compounded at −10.8% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−7 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -3.4% · Net -6.9%
ROE
FY2025 · ROE -58.7%
Each USD of equity lost 59 cents this year.
The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · |
| EBITDA $B | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| Income tax $B | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income $B | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · |
| EPS, diluted $ | −0.01 | −0.01 | 0.02 | −0.07 | −0.14 | −0.22 | −0.17 | 0.09 | −0.06 | −0.27 | −0.35 | · | −0.23 | −0.01 | −0.01 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −58.7 | −101.9 | 291.8 | −593.9 | −210.8 | −110.4 | −56.1 | 43.0 | −33.1 | −77.5 | −55.2 | −8.9 | −55.4 | · | · |
| Shares out B | 0.18 | 0.18 | 0.16 | 0.15 | 0.11 | 0.10 | 0.10 | 0.09 | 0.09 | 0.06 | 0.05 | 0.03 | 0.02 | 0.01 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 72 reconciliationsAUDITED
Reconciled in 15 of 19 fiscal years. 23 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011